chatGPT:
Here’s a concise review of the article.
Summary
Chris Masterjohn’s article, published April 21, 2026, argues that benzodiazepines should not be understood mainly as “brain GABA drugs,” but as whole-body drugs with important mitochondrial targets. He says both ongoing benzodiazepine use and benzodiazepine withdrawal can produce mitochondrial dysfunction, and he presents this as a unifying explanation for the broad range of withdrawal symptoms and for signals of increased mortality seen in observational studies. (chrismasterjohnphd.substack.com)
The visible part of the piece makes four main moves. First, it reframes benzodiazepines as system-wide rather than brain-specific, noting tissue distribution outside the brain and pointing to the historical “peripheral benzodiazepine receptor,” now TSPO, on the mitochondrial outer membrane. Second, it links benzodiazepine withdrawal symptoms, including long-lasting or “protracted” symptoms, to an energy failure or supply-demand imbalance rather than only rebound anxiety or GABA adaptation. Third, it uses observational mortality data to suggest a possible “physiological trap,” where both use and discontinuation are associated with harm. Fourth, it implies that individual benzodiazepines may differ in mitochondrial effects, with clonazepam and diazepam highlighted as examples. (chrismasterjohnphd.substack.com)
The article’s linked evidence does support some of the background pieces. There is a 2016 meta-analysis reporting an association between anxiolytic/hypnotic use and increased mortality, and a 2023 JAMA Network Open target-trial emulation found that among stable long-term benzodiazepine users, discontinuation was associated with a 1.6-fold mortality risk over 12 months, with small absolute increases in mortality and some other adverse outcomes. Separately, TSPO is indeed a mitochondrial outer membrane protein historically known as the peripheral benzodiazepine receptor. (Sage Journals)
What is novel here
The most novel part is not new primary data, at least in the visible portion. The novelty is the synthesis: Masterjohn tries to make mitochondrial biology the central explanatory framework for benzodiazepine effects and withdrawal, rather than treating mitochondrial effects as a side note to GABAergic pharmacology. (chrismasterjohnphd.substack.com)
More specifically, the article’s distinctive contributions are:
- It puts TSPO/mitochondria at the center of the benzodiazepine story, rather than as a secondary receptor footnote. (chrismasterjohnphd.substack.com)
- It proposes that withdrawal itself is best interpreted as mitochondrial dysfunction / energetic failure, which is a much stronger claim than standard guidance, which usually discusses dependence, withdrawal, seizures, rebound symptoms, and tapering complexity without making mitochondria the core mechanism. (chrismasterjohnphd.substack.com)
- It tries to connect very different observations — tissue distribution, TSPO biology, prolonged symptoms, and mortality associations — into one mechanistic model. (chrismasterjohnphd.substack.com)
So the article is conceptually original in how aggressively it unifies these threads. But based on what is visible, it does not appear to present new experiments, a new cohort, or a new systematic review. (chrismasterjohnphd.substack.com)
Critique
The article is interesting and thought-provoking, but I would treat its headline claim — “benzodiazepine withdrawal is mitochondrial dysfunction” — as a hypothesis or interpretive framework, not something established to a clinical standard.
The strongest point in its favor is that it is not crazy on first principles. Benzodiazepines do have biology outside classical synaptic GABA(_A) receptor modulation; TSPO is real, mitochondrial localization is real, and experimental literature does show that some benzodiazepines or related ligands can affect mitochondrial respiration, oxidative stress pathways, steroidogenesis, or related signaling. (PMC)
But there are several important weaknesses.
First, the article appears to move too quickly from “benzodiazepines can affect mitochondria” to “withdrawal is mitochondrial dysfunction.” That is a much stronger causal statement. Standard clinical guidance on benzodiazepine tapering emphasizes physical dependence, withdrawal risk, rebound symptoms, and the dangers of rapid tapering, but it does not endorse a mitochondrial model as the established mechanism. (Springer Nature Link)
Second, the mortality evidence is observational and confounded. The 2016 meta-analysis found an association between anxiolytic/hypnotic use and mortality, but later work has questioned how much of that is due to underlying illness, frailty, psychiatric burden, or other confounding. A 2017 BMJ cohort study concluded there was either no increase or at most a minor increase in all-cause mortality with benzodiazepine initiation, much smaller than earlier reports. (Sage Journals)
Third, even the 2023 discontinuation study, while important, does not prove a mitochondrial mechanism. It found higher mortality and other harms after discontinuation among stable long-term users, but the authors themselves framed this as an association in an emulated target trial, not proof of causality, and residual confounding remains plausible. It also does not directly tell us whether the risk signal is due to withdrawal severity, underlying patient complexity, taper speed, substitution patterns, illicit drug exposure, or some mixture of these. (JAMA Network)
Fourth, the article may be overstating the certainty of some mechanistic details. TSPO biology is real, but aspects of TSPO function, especially its exact role in cholesterol transport and steroidogenesis, have been debated and refined over time. So “mitochondrial target exists” is firm, while “this explains the syndrome” is much less firm. (PMC)
Fifth, the visible article uses strong rhetoric such as knowledge being “buried,” which weakens it scientifically. That kind of framing may be rhetorically effective, but it is not evidence. A more persuasive version would quantify receptor affinity, therapeutic tissue concentrations, concentration-response relationships, and direct human evidence linking withdrawal states to mitochondrial biomarkers. (chrismasterjohnphd.substack.com)
Sixth, the article is only partially accessible without subscription, so some of the deeper mechanistic argument may be in the paywalled sections. Based on the visible portion, I cannot verify whether it ultimately supplies the crucial missing bridge: direct human evidence that benzodiazepine withdrawal symptoms track with measurable mitochondrial dysfunction and that this outperforms conventional neuroadaptation models. (chrismasterjohnphd.substack.com)
Bottom line
My assessment is:
Useful idea: yes.
Established conclusion: no.
The article is valuable as a provocative mechanistic reinterpretation of benzodiazepine use and withdrawal. Its strongest contribution is to push readers to take extra-CNS and mitochondrial effects seriously. But the evidence visible to me does not justify treating “benzodiazepine withdrawal is mitochondrial dysfunction” as a settled fact. The more defensible wording would be:
benzodiazepines likely have clinically relevant mitochondrial effects, and mitochondrial dysfunction may contribute to some withdrawal phenomena, but this remains unproven as the primary or universal mechanism. (chrismasterjohnphd.substack.com)
If you want, I can do a second pass focused just on the mechanistic plausibility of the mitochondrial claim and separate out which parts are strong, weak, or speculative.